Complete response of brain metastases to irinotecan-based chemotherapy

被引：12

作者：

Chou, R

Chen, A

Lau, D

机构：

[1] Univ Calif Davis, Davis Med Ctr, Dept Radiat Oncol, Sacramento, CA 95817 USA

[2] Univ Calif Davis, Davis Med Ctr, Div Hematol Oncol, Sacramento, CA 95817 USA

来源：

JOURNAL OF CLINICAL NEUROSCIENCE | 2005年 / 12卷 / 03期

关键词：

brain metastases; irinotecan; whole brain radiation;

D O I：

10.1016/j.jocn.2004.08.007

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：242 / 245

页数：4

共 11 条

[1]

Abrey Lauren E, 2003, Clin Adv Hematol Oncol, V1, P231

[2]

Agarwala S S, 2000, Oncologist, V5, P144, DOI 10.1634/theoncologist.5-2-144

[3]

ANDREWS DW, IN PRESS LANCET

[4]

Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates [J].